Arg-Gly-Asp-Cys
Arg-Gly-Asp-Cys is the binding motif of fibronectin to cell adhesion molecules, and can inhibit platelet aggregation and fibrinogen binding.
For research use only. We do not sell to patients.
- CAS No.: 109292-46-8
- Formula: C15H27N7O7S
- Molecular Weight:449.48
-
Storage:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Platelet | IC50 |
322 μM
Compound: RGDC
|
Antiplatelet activity in citrated human platelet rich plasma assessed as inhibition of ADP-induced platelet aggregation incubated for 10 mins at 37 degC by light transmission aggregometry
Antiplatelet activity in citrated human platelet rich plasma assessed as inhibition of ADP-induced platelet aggregation incubated for 10 mins at 37 degC by light transmission aggregometry
|
[PMID: 25457125] |
RGDC immobilizes peptide onto DAH-CMTMC is found to be about 15.3 μg/mg of chitosan derivative by amino acid analysis (AAA). RGDC-functionalized chitosan may lead to enhanced wound healing (viability >140%). RGDC-functionalizes chitosan derivatives exhibit in vitro wound healing properties by enhancing fibroblast proliferation and adhesion. RGDC-DAH-CMTMC favors cell growth and an increase in cellular proliferation compared to the control cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 109292-46-8
-
Appearance Solid
-
Molecular Weight 449.48
-
Formula C15H27N7O7S
-
Color White to off-white
-
Sequence Shortening
RGDC
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
H2O
Peptide Solubility and Storage Guidelines:
1. Calculate the length of the peptide.
2. Calculate the overall charge of the entire peptide according to the following table:
| Contents | Assign value | |
| Acidic amino acid | Asp (D), Glu (E), and the C-terminal -COOH. | -1 |
| Basic amino acid | Arg (R), Lys (K), His (H), and the N-terminal -NH2 | +1 |
| Neutral amino acid | Gly (G), Ala (A), Leu (L), Ile (I), Val (V), Cys (C), Met (M), Thr (T), Ser (S), Phe (F), Tyr (Y), Trp (W), Pro (P), Asn (N), Gln (Q) | 0 |
3. Recommended solution:
| Overall charge of peptide | Details |
| Negative (<0) |
1. Try to dissolve the peptide in water first. 2. If water fails, add NH4OH (<50 μL). 3. If the peptide still does not dissolve, add DMSO (50-100 μL) to solubilize the peptide. |
| Positive (>0) |
1. Try to dissolve the peptide in water first. 2. If water fails, try dissolving the peptide in a 10%-30% acetic acid solution. 3. If the peptide still does not dissolve, try dissolving the peptide in a small amount of DMSO. |
| Zero (=0) |
1. Try to dissolve the peptide in organic solvent (acetonitrile, methanol, etc.) first. 2. For very hydrophobic peptides, try dissolving the peptide in a small amount of DMSO, and then dilute the solution with water to the desired concentration. |
Protocol
Human precursor dermal fibroblasts (HDF, human dermal progenitor cells, 12 week male donor) are use in the assay. WST-1 assay is used to assess the viability of HDF when incubated with chitosan derivatives. For this study, HDF are seeded in a 96-well plate at a density of 6×103 cells/cm2. To each well, 100 μL of cell suspension is added and incubated for 48 h in order to allow cell attachment. DMEM is then replaced by 100 μL of CMTMC and RGDC-DAH-CMTMC suspension at concentrations of 0.25 mg/mL, 0.5 mg/mL and 1 mg/mL, respectively. Cell viability under polymer incubation is evaluated during 2, 4 and 7 days. SDS (1%) is used as negative control. The polymer solution is changed every 3 days. 100 μL of WST-1 (1:10 dilution in DMEM) are added in each well after removing the polymer suspension and incubated for 0.5-2 h. Absorbance is recorded with a BioTek Microplate reader at two different wavelengths (450 and 690 nm). The viability is presented as percentage compared to the positive control group (cells in DMEM supplemented with 10% fetal calf serum). All experiments are carried out in triplicates.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (268 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)